Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 269Neoplasms 148Breast Neoplasms 146Colorectal Neoplasms 128Neoplasm Metastasis 96Prostatic Neoplasms 95Multiple Myeloma 94Ovarian Neoplasms 93Lung Neoplasms 88Squamous Cell Carcinoma of Head and Neck 64Pancreatic Neoplasms 64Recurrence 62Endometrial Neoplasms 58Small Cell Lung Carcinoma 52Melanoma 52Stomach Neoplasms 50Leukemia, Lymphocytic, Chronic, B-Cell 48Carcinoma, Renal Cell 47Leukemia, Myeloid, Acute 46Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 40Urinary Bladder Neoplasms 38Triple Negative Breast Neoplasms 38Parkinson Disease 4, Autosomal Dominant Lewy Body 38Head and Neck Neoplasms 38Lymphoma, Large B-Cell, Diffuse 36Carcinoma, Hepatocellular 35Esophageal Neoplasms 32Lymphoma, Follicular 30Colonic Neoplasms 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Infectious Mononucleosis × 30 days × Clear all
NCT05164094 2026-05-06

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

ModernaTX, Inc.

Phase 1/2 Active not recruiting
867 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡